(MedPage Today) — The first head-to-head randomized clinical trial to compare biologics in severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma showed an advantage to dupilumab (Dupixent) over omalizumab (Xolair).
In…
Source link : https://www.medpagetoday.com/meetingcoverage/ers/117692
Author :
Publish date : 2025-09-29 15:29:00
Copyright for syndicated content belongs to the linked Source.
